FERMT1 Is a Prognostic Marker Involved in Immune Infiltration of Pancreatic Adenocarcinoma Correlating with m6A Modification and Necroptosis

Wu, Qian; Li, Jin; Wang, Pei; Peng, Qihang; Kang, Zhongcui; Deng, Yiting; Li, Jiayi; Yan, Dehong; Ge, Feng; Chen, Ying

doi:10.3390/genes14030734

Cited by 4 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive correlation between FERMT1 and the three main genes responsible for necroptosis (RIPK1, RIPK3, and MLKL) indicates that FERMT1 may serve as NRGs in PDAC. It was shown that individuals with elevated levels of FERMT1 respond more to Palbociclib (CDK4/6 inhibitor), TAE-226 (focal adhesion kinase selective inhibitor), and AM-5992 (AMG-925; dual inhibitor of CDK4 and FLT3), which can be combined in combination therapy to enhance the treatment of pancreatic cancer [183]. There is evidence that stimulating necroptosis can be a successful supplementary treatment for pancreatic cancer.…”

Section: Combination Therapymentioning

confidence: 99%

Genome, Metabolism, or Immunity: Which Is the Primary Decider of Pancreatic Cancer Fate through Non-Apoptotic Cell Death?

Barar,

Shi

2023

Biomedicines

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor characterized by poor prognosis and resistance to treatment. Resistance to apoptosis, a cell death process, and anti-apoptotic mechanisms, are some of the hallmarks of cancer. Exploring non-apoptotic cell death mechanisms provides an opportunity to overcome apoptosis resistance in PDAC. Several recent studies evaluated ferroptosis, necroptosis, and pyroptosis as the non-apoptotic cell death processes in PDAC that play a crucial role in the prognosis and treatment of this disease. Ferroptosis, necroptosis, and pyroptosis play a crucial role in PDAC development via several signaling pathways, gene expression, and immunity regulation. This review summarizes the current understanding of how ferroptosis, necroptosis, and pyroptosis interact with signaling pathways, the genome, the immune system, the metabolism, and other factors in the prognosis and treatment of PDAC.

show abstract

Section: Combination Therapymentioning

confidence: 99%

Genome, Metabolism, or Immunity: Which Is the Primary Decider of Pancreatic Cancer Fate through Non-Apoptotic Cell Death?

Barar,

Shi

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

The integrin adhesome and control of anti-tumour immunity

Webb,

Black,

Barth

et al. 2024

Biochemical Society Transactions

View full text Add to dashboard Cite

It is widely regarded that the anti-tumour immune response drives clearance of tumours and leads to prolonged survival in patients. However, tumours are adept at reprogramming the surrounding microenvironment to an immunosuppressive milieu to prevent successful immune directed killing. Adhesion of cells to the extracellular matrix is essential for regulating cellular processes such as survival, proliferation and migration. This adhesion is largely conducted via integrins and their related intracellular signalling networks. Adhesion proteins such as focal adhesion kinase (FAK) are expressed in both tumour cells and cells of the surrounding microenvironment, and are often dysregulated in cancers. Recent work has demonstrated that adhesion proteins are contributing to regulation of the immunosuppressive microenvironment within tumours, and could provide a new avenue to target in combination with immunotherapies. Here, we provide an overview of the effort being made to elucidate the roles adhesion proteins play in modulating anti-tumour responses within a variety of cancer settings. In particular we focus on the multifaceted role of FAK within the tumour immune microenvironment. Finally, we summarise the data in clinical trials, where targeting FAK is being exploited to prime the tumour microenvironment and create potent responses when combined with immunotherapies.

show abstract

WITHDRAWN: Identifying diagnostic markers and constructing a prognostic model for pancreatic cancer based on microarray and bioinformatic analysis

Zhang,

Liu,

Qian

et al. 2024

Preprint

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide. The lack of effective diagnostic biomarkers and therapeutic targets makes PC difficult to screen and treat. The aim of this study was to develop a diagnostic and survival-related gene signature for PC to construct a prognostic model. An Arraystar RNA microarray was used to identify differentially expressed genes (DEGs) in clinical plasma samples between the PC group and the control group. We performed weighted gene co-expression network analysis (WGCNA) to identify significant modules of DEGs in the Gene Expression Omnibus (GEO) cohort and to obtain potential diagnostic hub genes by intersecting the significant module genes with microarray-derived messenger RNA (mRNA). In addition, survival analysis and univariate and multivariate Cox regression analyses were performed on the hub genes to construct a prognostic model. Our microarray data revealed 228 significantly upregulated mRNA in the PC group compared with the control group. Moreover, we identified 5 feature mRNA (FERMT1, S100A14, KCNN4, PKM, and ITGA3) with good diagnostic performance. According to survival analysis based on The Cancer Genome Atlas (TCGA) dataset, higher expression of the hub genes was related to a poorer survival rate in patients with PC. Univariate and multivariate Cox proportional hazard analyses revealed that the expression of FERMT1, S100A14, and ITGA3 was anindependent risk factor for poor prognosis. Our results revealed the potential biomarkers for the prediction of PC prognosis in addition to clinicopathological factors. Moreover, this study provides new insights into the molecular mechanisms of PC.

show abstract

FERMT1 Is a Prognostic Marker Involved in Immune Infiltration of Pancreatic Adenocarcinoma Correlating with m6A Modification and Necroptosis

Cited by 4 publications

References 62 publications

Genome, Metabolism, or Immunity: Which Is the Primary Decider of Pancreatic Cancer Fate through Non-Apoptotic Cell Death?

Genome, Metabolism, or Immunity: Which Is the Primary Decider of Pancreatic Cancer Fate through Non-Apoptotic Cell Death?

The integrin adhesome and control of anti-tumour immunity

WITHDRAWN: Identifying diagnostic markers and constructing a prognostic model for pancreatic cancer based on microarray and bioinformatic analysis

Contact Info

Product

Resources

About